Clinical trial
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With…
NCT00051584 · Seagen Inc., Industry · Terminated
Key facts
| NCT number | NCT00051584 |
|---|---|
| Title | Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer |
| Official title | A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer |
| Lead sponsor | Seagen Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | SGN-15 (cBR96-Doxorubicin Immunoconjugate), Gemzar (Gemcitabine) |
| Enrollment | 60 |
| Completion | May 1, 2003 |
| First posted | Jan 15, 2003 |
| Last update posted | Oct 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: